- Home
- Applications
- platelets
Refine by
Platelets Product Applications
19 applications found
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots.https://www.bocsci.com/prasugrel-impurity-ii-cas-1391194-39-0-item-483208.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots.https://www.bocsci.com/prasugrel-impurity-iii-cas-1391194-50-5-item-483210.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots.https://www.bocsci.com/prasugrel-impurity-i-cas-1391194-45-8-item-483209.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots. ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
Platelets are one of the small components in blood circulation participating in primary hemostasis and thrombosis. Besides coagulation and wound healing, numerous research articles demonstrate the capability of human platelet lysate (hPL) in research, regenerative medicine and clinical applications. ...
ByAventaCell BioMedical Corp based in Atlanta, GEORGIA (US) (USA)
Growth performance of Madin-Darby canine kidney (MDCK NBL-2) cells in media containing Simplified Platelet Lysate (SimPL), fetal bovine serum (FBS), or human platelet lysate (hPL). ...
ByAgulos Biotech, LLC based in Lake Mills, WISCONSIN (USA)
The Endomimetics bionanomatrix provides the following key attributes: A reservoir for sustained release of nitric oxide, which stimulates healthy normal endothelial cell coverage while limiting smooth muscle cell proliferation and platelet adhesion. The sustained release of nitric oxide promotes normal healthy vasodilation. ...
ByEndomimetics based in Birmingham, ALASKA (USA)
Now the qCell T series provides a sophisticated platform with outstanding potential to face such challenging situations due to its capability to evaluate the plasmatic pathway as well as the platelets in real time (Hussain et al, 2016; 2015; 2015; 2013). Recent developments in the field 'molecular imprinting' employing the QCM technology promise platelet aggregation sensing in real patients by synthetic biomimics in near future (Hussain, 2016). ...
By3T Analytik GmbH & Co. KG based in Neuhausen ob Eck, GERMANY
Growth of FO myeloma cells in media containing Simplified Platelet Lysate (SimPL-Serum) and fetal bovine serum (FBS). Cells were grown in standard DMEM basal media containing penicillin, streptomycin, and GlutaMAX™ with 10% (v/v) FBS or 10% SimPL-Serum in 6-well plates. ...
ByAgulos Biotech, LLC based in Lake Mills, WISCONSIN (USA)
Collagen fibrils in collagen powder helps to trap platelets and assist in forming a clot to stop bleeding. Extracellular matrix scaffolds are widely used in hernia repair and other areas of soft tissue weakness. ...
ByViscus Biologics LLC based in Cleveland, OHIO (USA)
Growth performance of 3T3-L1 fibroblasts in media containing Simplified Platelet Lysate (SimPL) and fetal bovine serum (FBS). 3T3-L1 fibroblasts were grown in DMEM/F12 basal media containing penicillin, streptomycin, and GlutaMAX™ with either 10% (v/v) FBS or 10% SimPL. ...
ByAgulos Biotech, LLC based in Lake Mills, WISCONSIN (USA)
Growth performance of human adipose-derived mesenchymal stem cells in media containing Simplified Platelet Lysate (SimPL) and fetal bovine serum (FBS). Cells were grown in standard DMEM/F12 basal media containing penicillin, streptomycin, and GlutaMAX™ with either 10% (v/v) FBS or 2% SimPL (left). ...
ByAgulos Biotech, LLC based in Lake Mills, WISCONSIN (USA)
We adapted an autologous ex-vivo gene therapy method to load the patient’s own TEMs precursors, that are hematopoietic stem and progenitor cells (HSPCs), with an immunotherapeutic transgene sequence. By re-introducing gene-modified HSPCs into the patient, we seek to take advantage of the self-renewing and multi-differentiation capability of HSPCs to enable durable and potentially long-term effects following a single ...
ByGenenta Science based in Milano, ITALY
Therapeutic apheresis works to remove degenerative, pro-cancer and pro-inflammatory compounds that contribute to the progression of life-threatening illness— allowing the body a chance to deeply detoxify, while enhancing the effects of other therapies and supporting optimal ...
ByEliaz Therapeutics based in Santa Rosa, CALIFORNIA (USA)
Preventative care for obstetric related venous thromboembolism (VTE). Pulmonary embolism (PE) is the leading cause of maternal death in the developed world. Patients are 5 times more likely to develop deep vein thrombosis (DVT) during pregnancy2. The UK incidence of VTE in pregnancy and the puerperium is 1–2 episodes per 1,000 patients3 and accounts for 10% of all maternal deaths in the United ...
ByFirstkind Ltd based in High Wycombe, UNITED KINGDOM
The development of laser technology extends back to the time around 1920 to Albert Einstein. After the first laser was constructed in 1960 the advances in laser technology developed in leaps and ...
ByHeltschl Medizintechnik GmbH based in Schlüsslberg, AUSTRIA
Traditionally, primary treatment for DVT has focused on anticoagulation, rather than thrombus removal. Anticoagulation therapy does not remove existing thrombus but rather prevents the propagation of the ...
BySurmodics, Inc. based in Eden Prairie, MINNESOTA (USA)
Endovascular clot removal methods can provide immediate symptom relief and, by removing clot early, physicians can identify an underlying obstructive lesion that may require a stent. Current endovascular treatment methods involve catheter-directed thrombolysis (CDT), percutaneous mechanical thrombectomy (PMT), balloon venoplasty, iliac vein stenting, and manual ...
BySurmodics, Inc. based in Eden Prairie, MINNESOTA (USA)
The classical (but rarely observed) malaria attack lasts 6–10 ...
ByAmivas (US), LLC based in Frederick, MARYLAND (USA)